Why is it in the news?

• Project ANAGRANINF is funded by the Technology Development Board for the development of a novel class of antibiotics targeting Gram-negative bacterial infections.

More about the news

• The project is a collaboration between companies from India and Spain, combining expertise and resources from both countries.
• Objective: To develop a lead compound, specifically an antibiotic, aimed at combating critical Gram-negative pathogens.
• Focus: Addressing the challenge of antimicrobial resistance (AMR) infections, particularly those caused by Gram-negative bacteria which are increasingly resistant to existing antibiotics.
• The compounds developed in the project will adhere to the criteria outlined by the World Health Organization for tackling AMR infections, ensuring their effectiveness in combating resistant strains.
• Gram-negative bacteria: These bacteria pose a significant threat as they are resistant to multiple drugs, including many commonly used antibiotics, making them difficult to treat.